{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:39:54Z","timestamp":1784947194372,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-12876-6","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:50:43Z","timestamp":1747443043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience"],"prefix":"10.1186","volume":"25","author":[{"given":"Neda","family":"Yaghoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalda","family":"Metghalchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Shahrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"12876_CR1","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A et al. Global Cancer Observatory: Cancer Today. Iran: Islamic Republic of; 2022."},{"key":"12876_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41043-025-00738-0","volume":"44","author":"BD Teli","year":"2025","unstructured":"Teli BD, Behzadifar M, Beiranvand M, Rezapour A, Ehsanzadeh SJ, Azari S, et al. The economic burden of breast cancer in Western Iran: a cross-sectional cost-of-illness study. J Health Popul Nutr. 2025;44:16.","journal-title":"J Health Popul Nutr"},{"key":"12876_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12962-023-00470-8","volume":"21","author":"FS Jalali","year":"2023","unstructured":"Jalali FS, Keshavarz K, Seif M, Akrami M, Jafari A, Ravangard R. Economic burden of breast cancer: a case of Southern Iran. Cost Eff Resour Alloc. 2023;21:58.","journal-title":"Cost Eff Resour Alloc"},{"key":"12876_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab \u2014 Mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39\u201351.","journal-title":"N Engl J Med"},{"key":"12876_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00280-009-1208-1","volume":"65","author":"A Davoli","year":"2010","unstructured":"Davoli A, Hocevar BA, Brown TL. Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol. 2010;65:611\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"key":"12876_CR6","first-page":"1","volume":"15","author":"KS Vega Cano","year":"2023","unstructured":"Vega Cano KS, Marmolejo Casta\u00f1eda DH, Escriv\u00e1-de-Roman\u00ed S, Saura C. Systemic therapy for HER2-Positive metastatic breast cancer: current and future trends. Cancers (Basel). 2023;15:1\u201319.","journal-title":"Cancers (Basel)"},{"key":"12876_CR7","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097\u2013108.","journal-title":"Clin Cancer Res"},{"key":"12876_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the Antibody\u2013Drug conjugate, [fam-] trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer therapy. Chem Pharm Bull. 2019;67:173\u201385.","journal-title":"Chem Pharm Bull"},{"key":"12876_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039\u201346.","journal-title":"Cancer Sci"},{"key":"12876_CR10","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-Positive breast Cancer with Trastuzumab-DM1, an Antibody\u2013Cytotoxic drug conjugate. Cancer Res. 2008;68:9280\u201390.","journal-title":"Cancer Res"},{"key":"12876_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"TT Junttila","year":"2011","unstructured":"Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"12876_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop IE, Kim S-B, Martin AG, LoRusso PM, Ferrero J-M, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743\u201354.","journal-title":"Lancet Oncol"},{"key":"12876_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jval.2023.11.004","volume":"27","author":"R Mudumba","year":"2024","unstructured":"Mudumba R, Chan H-H, Cheng Y-Y, Wang C-C, Correia L, Ballreich J, et al. Cost-Effectiveness analysis of trastuzumab Deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast Cancer in the united States. Value Heal. 2024;27:153\u201363.","journal-title":"Value Heal"},{"key":"12876_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, et al. Trastuzumab Deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105\u201317.","journal-title":"Lancet"},{"key":"12876_CR15","first-page":"243","volume":"9","author":"N Nafissi","year":"2018","unstructured":"Nafissi N, Khayamzadeh M, Zeinali Z, Pazooki D, Hosseini M, Akbari ME. Epidemiology and histopathology of breast cancer in Iran versus other middle Eastern countries. Middle East J Cancer. 2018;9:243\u201351.","journal-title":"Middle East J Cancer"},{"key":"12876_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10198-023-01617-3","volume":"25","author":"JHJ Paulissen","year":"2024","unstructured":"Paulissen JHJ, Seddik AH, Dunton KJ, Livings CJ, van Hulst M, Postma MJ, et al. Cost-effectiveness model of trastuzumab Deruxtecan as second-line treatment in HER2-positive unresectable and\/or metastatic breast cancer in Finland. Eur J Heal Econ. 2024;25:689\u201399.","journal-title":"Eur J Heal Econ"},{"key":"12876_CR17","doi-asserted-by":"crossref","unstructured":"Yang J, Han J, Zhang Y, Muhetaer M, Chen N, Yan X. Cost-effectiveness analysis of trastuzumab Deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Front Pharmacol. 2022;13:1\u201311.","DOI":"10.3389\/fphar.2022.924126"},{"key":"12876_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.breast.2022.10.010","volume":"66","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Liu K, Wang M, Wang K, Zhu H. Trastuzumab Deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis. Breast. 2022;66:191\u20138.","journal-title":"Breast"},{"key":"12876_CR19","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1007\/s12325-022-02273-4","volume":"39","author":"J Wang","year":"2022","unstructured":"Wang J, Yi Y, Wan X, Zeng X, Peng Y, Tan C. Cost-Effectiveness analysis of trastuzumab Deruxtecan versus trastuzumab emtansine in human epidermal growth factor receptor 2-Positive metastatic breast Cancer in the USA. Adv Ther. 2022;39:4583\u201393.","journal-title":"Adv Ther"},{"key":"12876_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-11-139","volume":"11","author":"MW Hoyle","year":"2011","unstructured":"Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:1\u201314.","journal-title":"BMC Med Res Methodol"},{"key":"12876_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.breast.2020.03.001","volume":"51","author":"T-C Chou","year":"2020","unstructured":"Chou T-C, Chiang S-C, Ko Y. Health state utilities for metastatic breast cancer in Taiwan. Breast. 2020;51:57\u201364.","journal-title":"Breast"},{"key":"12876_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95:683\u201390.","journal-title":"Br J Cancer"},{"key":"12876_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/curroncol30010010","volume":"30","author":"E McKevitt","year":"2023","unstructured":"McKevitt E, Saleeb M, Liu G, Warburton R, Pao JS, Dingee C, et al. Differences in preoperative Health-Related quality of life between women receiving mastectomy or breast conserving surgery in a prospectively recruited cohort of breast Cancer patients. Curr Oncol. 2023;30:118\u201329.","journal-title":"Curr Oncol"},{"key":"12876_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.30773\/pi.2020.0286","volume":"18","author":"KH Seol","year":"2021","unstructured":"Seol KH, Bong SH, Kang DH, Kim JW. Factors associated with the quality of life of patients with cancer undergoing radiotherapy. Psychiatry Investig. 2021;18:80\u20137.","journal-title":"Psychiatry Investig"},{"key":"12876_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus trastuzumab emtansine for breast Cancer. N Engl J Med. 2022;386:1143\u201354.","journal-title":"N Engl J Med"},{"key":"12876_CR26","doi-asserted-by":"crossref","unstructured":"Daneshmand A, Jahangard E, Abdollah-Milani M. A time preference measure of the social discount rate for Iran. J Econ Struct. 2018;7:1\u201310.","DOI":"10.1186\/s40008-018-0127-x"},{"key":"12876_CR27","unstructured":"Central Bank of Islamic Republic of Iran. https:\/\/cbi.ir\/. Accessed 3 May 2025."},{"key":"12876_CR28","doi-asserted-by":"publisher","first-page":"17933","DOI":"10.1007\/s00432-023-05496-2","volume":"149","author":"S Hu","year":"2023","unstructured":"Hu S, Wu Y, Luan J, Wang S, Fan G. Cost\u2013utility analysis of trastuzumab Deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting. J Cancer Res Clin Oncol. 2023;149:17933\u201342.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12876-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12876-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12876-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T13:02:53Z","timestamp":1747486973000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12876-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12876"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12876-6","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"711"}}